Great. Then I guess all we need to know is how many of the 145 are “open for business” with Excellagen usage... training complete, product stocked... and what the rollout looks like with CV, since it will be surely affecting the VA thru next spring at least.

We deserve some sort of forecast on that. We can’t wait another year to determine whether this product can ramp up or not. And surely Joe and team have a plan for the next year for Excellagen that does not rely on a CV vaccine/therapy (whether it’s ours or someone else’s).